Research programme: mitogen-activated protein kinase-activated protein kinase-2 pathway inhibitors - Confluence Life Sciences

Drug Profile

Research programme: mitogen-activated protein kinase-activated protein kinase-2 pathway inhibitors - Confluence Life Sciences

Alternative Names: MK2 pathway inhibitor; MK2 PI

Latest Information Update: 07 Jan 2015

Price : $50

At a glance

  • Originator Confluence Life Sciences
  • Class
  • Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 07 Jan 2015 Early research in Inflammation in USA (unspecified route)
  • 07 Jan 2015 Research programme: mitogen-activated protein kinase-activated protein kinase-2 pathway inhibitors - Confluence Life Sciences is available for licensing as of 07 Jan 2015. http://www.confluencelifesciences.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top